TRCT
FTH

Tower Research Capital (TRC)’s Faeth Therapeutics FTH Stock Holding History

Tower Research Capital (TRC)’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3K Sell
650
-846
-57% -$19.6K ﹤0.01% 3723
2026
Q1 		$47.2K Buy
+1,496
New +$29.9K ﹤0.01% 2788
2025
Q2 		– Sell
-270
Closed -$2.13K – 5555
2025
Q1 		$2.13K Sell
270
-2
-0.7% -$19 ﹤0.01% 4586
2024
Q4 		$2.67K Sell
272
-79
-23% -$793 ﹤0.01% 4795
2024
Q3 		$4.2K Sell
351
-3
-0.8% -$37 ﹤0.01% 4636
2024
Q2 		$4.39K Buy
354
+18
+5% +$374 ﹤0.01% 4788
2024
Q1 		$7.05K Sell
336
-86
-20% -$1.48K ﹤0.01% 4272
2023
Q4 		$5.84K Buy
422
+59
+16% +$805 ﹤0.01% 4799
2023
Q3 		$5.81K Sell
363
-11
-3% -$236 ﹤0.01% 4684
2023
Q2 		$8.52K Buy
374
+276
+282% +$8.08K ﹤0.01% 4423
2023
Q1 		$3K Sell
98
-8
-8% -$237 ﹤0.01% 5239
2022
Q4 		$3K Sell
106
-136
-56% -$4K ﹤0.01% 5231
2022
Q3 		$7K Buy
242
+23
+11% +$904 ﹤0.01% 4926
2022
Q2 		$10K Sell
219
-19
-8% -$712 ﹤0.01% 4482
2022
Q1 		$11K Buy
238
+57
+31% +$4.54K ﹤0.01% 4208
2021
Q4 		$21K Buy
181
+142
+364% +$21.2K ﹤0.01% 3619
2021
Q3 		$8K Sell
39
-32
-45% -$5.83K ﹤0.01% 4566
2021
Q2 		$14K Buy
71
+42
+145% +$10.4K ﹤0.01% 4186
2021
Q1 		$8K Buy
+29
New +$9.71K ﹤0.01% 4485

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Tower Research Capital (TRC)'s FTH Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Faeth Therapeutics (FTH) stake by 57% in Q2 2026, selling an estimated $19.6K and leaving 650 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

Tower Research Capital (TRC) first reported a position in FTH in Q1 2021 and has held it in 19 quarters since. The position peaked at $47.2K in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Tower Research Capital (TRC) held 650 shares of Faeth Therapeutics worth $16.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 846 Faeth Therapeutics shares in Q2 2026, an estimated $19.6K.
  • Faeth Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3723 holding.
  • Tower Research Capital (TRC) first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Faeth Therapeutics position peaked at $47.2K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.